I like to describe the BioCanRX network as
— it's a living organism that is constantly
exchanging information with the outside
world, the outside environment.
We have a definite goal in mind,
which is to advance
the translation of bio-therapies
to the clinic, and ultimately make
— make sure that these innovative,
new therapies make it to patients
that are afflicted with cancer.
BioCanRX has put together —
or brought together,
I should say – a group of different
stakeholders that we've called
the Cancer Stakeholder Alliance,
and it's a mixture.
It ebbs — there's an ebb and flow
to it, and around 45 to
50 not-for-profits in different
cancer indications
have come together in order
to work with us on delivering
on our mission and promise
of immunotherapy.
The NCE model is unique with
respect to any granting program
in that you have a group of researchers
and a group of stakeholders
that are in charge of the direction
of the program.
And that is unique, having that
kind of flexibility
where researchers are really
enabled to achieve these
incredible accomplishments for
the benefit of Canadians.
